In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
After finishing at $1.17 in the prior trading day, Nektar Therapeutics (NASDAQ: NKTR) closed at $1.07, down -8.55%. In other words, the price has decreased by -$8.55 from its previous closing price. On the day, 3.77 million shares were traded. NKTR stock price reached its highest trading level at $1.2 during the session, while it also had its lowest trading level at $1.04.
Ratios:
Our goal is to gain a better understanding of NKTR by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.24 and its Current Ratio is at 4.24. In the meantime, Its Debt-to-Equity ratio is 4.22 whereas as Long-Term Debt/Eq ratio is at 3.78.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Piper Sandler on November 04, 2024, initiated with a Overweight rating and assigned the stock a target price of $7.
On June 28, 2024, Rodman & Renshaw started tracking the stock assigning a Buy rating and target price of $2.Rodman & Renshaw initiated its Buy rating on June 28, 2024, with a $2 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 19 ’24 when Zalevsky Jonathan sold 6,866 shares for $1.28 per share. The transaction valued at 8,788 led to the insider holds 250,804 shares of the business.
Wilson Mark Andrew sold 5,651 shares of NKTR for $7,233 on Aug 19 ’24. The Chief Legal Officer now owns 225,263 shares after completing the transaction at $1.28 per share. On Aug 19 ’24, another insider, ROBIN HOWARD W, who serves as the President & CEO of the company, sold 14,881 shares for $1.28 each. As a result, the insider received 19,048 and left with 848,358 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NKTR now has a Market Capitalization of 197370064 and an Enterprise Value of 158966368. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.94 while its Price-to-Book (P/B) ratio in mrq is 4.04. Its current Enterprise Value per Revenue stands at 1.707 whereas that against EBITDA is -1.221.
Stock Price History:
Over the past 52 weeks, NKTR has reached a high of $1.93, while it has fallen to a 52-week low of $0.42. The 50-Day Moving Average of the stock is -17.32%, while the 200-Day Moving Average is calculated to be -12.80%.
Shares Statistics:
The stock has traded on average 1.22M shares per day over the past 3-months and 2378920 shares per day over the last 10 days, according to various share statistics. A total of 191.38M shares are outstanding, with a floating share count of 178.18M. Insiders hold about 3.41% of the company’s shares, while institutions hold 74.41% stake in the company. Shares short for NKTR as of 1730332800 were 5226179 with a Short Ratio of 4.30, compared to 1727654400 on 7306124. Therefore, it implies a Short% of Shares Outstanding of 5226179 and a Short% of Float of 3.63.
